0001209191-21-047756.txt : 20210722 0001209191-21-047756.hdr.sgml : 20210722 20210722163728 ACCESSION NUMBER: 0001209191-21-047756 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210720 FILED AS OF DATE: 20210722 DATE AS OF CHANGE: 20210722 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EHRLICH JASON CENTRAL INDEX KEY: 0001754049 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38682 FILM NUMBER: 211108028 MAIL ADDRESS: STREET 1: 1200 PAGE MILL ROAD CITY: PALO ALTO STATE: CA ZIP: 94304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kodiak Sciences Inc. CENTRAL INDEX KEY: 0001468748 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270476525 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1200 PAGE MILL RD CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 650-281-0850 MAIL ADDRESS: STREET 1: 1200 PAGE MILL RD CITY: PALO ALTO STATE: CA ZIP: 94304 FORMER COMPANY: FORMER CONFORMED NAME: Oligasis, LLC DATE OF NAME CHANGE: 20090721 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-07-20 0 0001468748 Kodiak Sciences Inc. KOD 0001754049 EHRLICH JASON 1200 PAGE MILL ROAD PALO ALTO CA 94304 0 1 0 0 See Remarks Common Stock 2021-07-20 4 S 0 2234 85.7604 D 57949 D Common Stock 2021-07-20 4 S 0 4716 86.5215 D 53233 D The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $85.085 to $86.085, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $86.09 to $86.89, inclusive. Chief Medical Officer and Chief Development Officer /s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich 2021-07-22